Mitochondrial Replacement Therapy

This is a special type of fertility treatment. It helps prevent certain genetic diseases that are passed down through the mother's egg. It uses a healthy egg and the father's sperm, but it replaces the egg's DNA with DNA from a healthy donor egg. This way, the child doesn't inherit mitochondrial diseases.

Procedure

What people who've had Mitochondrial Replacement Therapy report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Mitochondrial Replacement Therapy

Who It's For

Mitochondrial replacement therapy (MRT), also called mitochondrial donation, is a form of in vitro fertilization (IVF) designed to lower the chance that a woman passes a mitochondrial DNA disease to her child. Mitochondria are the structures inside cells that turn food into usable energy, and they carry a small set of their own genes, 37 in all, separate from the much larger store of DNA in the cell's nucleus. Children inherit mitochondrial DNA only from their mother, so a disease-causing change in it can reach her children. MRT moves the parents' nuclear DNA, which holds all but a small fraction of a person's DNA, out of the mother's egg and into an egg from a donor whose mitochondria are healthy. The child is genetically the parents' child, with mitochondrial DNA coming mainly from the donor. There are two methods. Maternal spindle transfer moves the mother's chromosomes into a donor egg before fertilization. Pronuclear transfer fertilizes both eggs first, then moves the parents' DNA from the patient's fertilized egg into the donor's. It is meant for women who carry a disease-causing mitochondrial variant at a level that puts their children at serious risk. That includes women in whom every copy of mitochondrial DNA carries the variant (called homoplasmy), which is passed to every child. Many women whose eggs carry a mix of healthy and affected copies (heteroplasmy) can instead use preimplantation genetic testing (PGT), in which IVF embryos are tested and one with a low level of the variant is chosen. In the United Kingdom (UK) program, MRT is offered only when PGT is unlikely to work. Other options include prenatal testing during a natural pregnancy, using a donor egg, adoption or deciding not to have children. MRT does not treat anyone who already has mitochondrial disease; it affects only a future child. MRT is legal in the UK, where the national fertility regulator must approve each individual case, and Australia has also approved both methods. It is not available in US clinics, because a federal funding restriction in place since 2015 prevents the Food and Drug Administration (FDA) from reviewing applications to use it. Use of these techniques to treat infertility in women without mitochondrial disease remains experimental.

Before the Procedure

Because MRT is offered only in specialized, regulated programs, preparation starts long before any egg is collected. Genetic specialists confirm the exact mitochondrial variant and how much of it the woman carries, which decides whether PGT or MRT makes more sense. Counseling for the woman, her partner and the egg donor runs through the whole pathway, and in the UK each case needs the regulator's approval before treatment. IVF success falls with age, so these conversations are worth starting early. The woman then has health and fertility assessments, followed by the same early steps as IVF: medicines to stimulate the ovaries so several eggs mature, then an egg retrieval procedure. A separate egg donor goes through stimulation and retrieval too, and her mitochondrial DNA is sequenced to make sure it does not carry a disease-causing variant. In the UK program the patient's eggs are usually frozen and stored until fresh donor eggs are available, so treatment can stretch over months and may involve more than one retrieval.

During the Procedure

The transfer itself happens in the laboratory, not in the woman's body. Eggs are fertilized by injecting a single sperm into each one, a standard IVF technique called intracytoplasmic sperm injection (ICSI). For pronuclear transfer, about 8 to 13 hours later an embryologist removes the two small packages of parental DNA (the pronuclei) from the patient's fertilized egg and places them in a donor's fertilized egg whose own pronuclei have been removed. Some of the mother's mitochondria can travel with the transferred DNA. The reconstructed embryos grow in the laboratory for 5 to 6 days. A single embryo is then placed in the uterus in the same way as a standard IVF embryo transfer, and other suitable embryos can be frozen for a later attempt. UK rules do not allow MRT embryos to be tested for the mother's variant before transfer.

Recovery & Aftercare

For the woman, recovery after egg retrieval and embryo transfer is the same as in ordinary IVF, and the fertility clinic gives instructions about medicines and when to take a pregnancy test. If she becomes pregnant, prenatal testing to check the baby's level of the variant can be discussed; in the first UK series, none of the women chose it. Children born after MRT are followed long term. In the UK program, each baby's blood is tested for the maternal variant after birth, and every child has a review by a pediatric heart specialist at 3 to 6 months. Ongoing follow-up looks at whether the small amount of maternal mitochondria stays low as the child grows and whether any health problems appear, because the long-term picture is not yet known.

Risks & Complications

The central limitation is that MRT reduces risk rather than guaranteeing prevention, because some of the mother's mitochondria can carry over. In the first UK report, published in 2025, the 8 babies born after pronuclear transfer had levels of the maternal variant in their blood ranging from undetectable to 16%, which researchers consider below the level that usually causes symptoms. Only easily sampled tissues such as blood can be tested, however, and laboratory studies show the carried-over mitochondria can sometimes increase. In a separate infertility program using spindle transfer, 1 of 6 babies had 40 to 60% of the mother's mitochondria. MRT is also less efficient than PGT. In the same UK program, 8 of 22 women (36%) who began pronuclear transfer had a confirmed pregnancy. Per embryo transfer, the pregnancy rate was about half that with PGT (20% versus 39%), mainly because more pregnancies ended very early after a positive test. Some women had no embryos suitable to transfer, and several retrieval cycles may be needed. Both the woman and the egg donor face the usual risks of egg stimulation and retrieval, including an excessive response of the ovaries to the medicines (ovarian hyperstimulation). Women with mitochondrial disease can also have a higher risk of pregnancy complications and early delivery. The 8 UK children were healthy at birth and developing normally when reported. One developed very high blood fats and a heart rhythm problem, both of which responded to treatment, and another had a type of infant seizure that went away on its own. Whether these were related to MRT is unclear, since IVF itself and some maternal conditions carry similar risks. Researchers have also raised theoretical concerns about a mismatch between the parents' nuclear DNA and the donor's mitochondria, though human population evidence has not shown harm from such combinations. With so few children born, long-term safety is unknown.

Questions to Ask Your Doctor

  1. 1.Is my mitochondrial variant better suited to preimplantation genetic testing or to mitochondrial replacement, and why?
  2. 2.Since MRT is not offered in the United States, where could I be considered for it, and what would eligibility, approval, cost and travel involve?
  3. 3.What is my realistic chance of a live birth at my age, and how many cycles might it take?
  4. 4.How might pregnancy affect my own mitochondrial condition, and who would manage that risk?
  5. 5.What follow-up would my child have, and what is known so far about long-term health after MRT?

Last reviewed • Oct 2026

Educational content, not medical advice.